Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glioblastoma multiforme treatment market will help companies and investors design strategic landscapes.
In India, the incidence of CNS tumors ranges from 5 to 10 per 100,000 population and accounts for 2% of all malignant cases. The incidence is growing, as per a hospital-based survey. The analysis of one year of registered CNS malignancies shows 38.7% cases of astrocytomas and 59.5% cases of high-grade gliomas.
There is no cure for the condition and the current treatment approaches are limited to improving the overall survival period of patients and relieving pain & symptoms to further improve the quality of life. The treatment of GBM is surgery in eligible patients, followed by radiation and chemotherapy. The Indian healthcare system comprises public and private sectors.
Public healthcare services vary drastically between urban and rural areas. In urban areas, public healthcare comprises few secondary and tertiary care, however, it is mostly limited to basic healthcare facilities in rural areas. Such a scenario increases the treatment burden on patients.
Horizon Databook provides a detailed overview of country-level data and insights on the India glioblastoma multiforme treatment market , including forecasts for subscribers. This country databook contains high-level insights into India glioblastoma multiforme treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account